Patents by Inventor Zelig Eshhar

Zelig Eshhar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7135295
    Abstract: A protein comprising an antigen-binding portion formed by two cooperating peptide sequences of FIGS. 3A and 3B of the application. The protein may alternatively comprise an altered antigen-binding portion where at least one of the peptide sequences is an altered sequence, an altered sequence being a sequence of FIG. 3A or 3B in which one or more of an amino acid residue has been added, deleted or replaced by another amino acid residue. The altered antigen-binding portion retains substantially the same antigen-binding specificity as said antigen-binding portion. Also disclosed are apparatus, systems and methods for detecting small assayed molecules in a sample using the protein.
    Type: Grant
    Filed: January 25, 2000
    Date of Patent: November 14, 2006
    Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Yeda Research and Development Co. Ltd., Biosensor Applications Sweden AB
    Inventors: Itamar Willner, Zelig Eshhar
  • Publication number: 20020137697
    Abstract: Chimeric receptor genes suitable for endowing lymphocytes with antibody-type specificity include a first gene segment encoding a single-chain Fv domain of a specific antibody and a second gene segment encoding all or part of the transmembrane and cytoplasmic domains, and optionally the extracellular domain, of an immune cell-triggering molecule. The chimeric receptor gene, when transfected to immune cells, expresses the antibody-recognition site and the immune cell-triggering moiety into one continuous chain. The transformed lymphocytes are useful in therapeutic treatment methods.
    Type: Application
    Filed: October 24, 1995
    Publication date: September 26, 2002
    Inventors: ZELIG A. ESHHAR, DANIEL SCHINDLER, TOVA WAKS, GIDEON GROSS, STEVEN A. ROSENBERG, PATRICK HWU
  • Patent number: 6090923
    Abstract: A cytotoxic protein expressed by human peripheral blood mononuclear cells is isolated in essentially homogenous form. This protein may be used to elicit production of polyclonal or monoclonal anti-cytotoxin antibodies.Hybridomas secreting anti-cytotoxin antibodies are identified by a solid phase bioassay. The antibodies are useful in the immunopurification of cytotoxins. The purified cytotoxic proteins are useful for the treatment of virus-infected or tumor target cells, either alone or in combination with interferon or a metabolic blocker.
    Type: Grant
    Filed: November 13, 1991
    Date of Patent: July 18, 2000
    Assignee: Yeda Research And Development Co. Ltd.
    Inventors: David Wallach, Talia Hahn, Zelig Eshhar
  • Patent number: 5912172
    Abstract: There are produced recombinant gene pairs which endow mononuclear cells, mainly various lymphocyte type cells, with antibody-type specificity. In specific gene pairs the rearranged gene pairs code for a binding site of an antibody molecule from the same species, of the T-cell receptor gene, or another species. Gene pairs of the invention code, for example, for antibodies specific towards tumor-specific antigens, viral antigens, modified self antigens, bacterial or fungal antigens, autoimmune type disease antigens and the like. The invention further relates to expression vectors for the effective transfection of such cell types comprising such a recombinant gene pair, to methods for producing same and to pharmaceutical compositions comprising as active ingredient an effective quantity of lymphocytes transfected with such gene pairs.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: June 15, 1999
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Zelig Eshhar, Gideon Gross, Tova Waks
  • Patent number: 5906936
    Abstract: There are produced recombinant gene pairs which endow mononuclear cells, mainly various lymphocyte type cells, with antibody-type specificity. In specific gene pairs the rearranged gene pairs code for a binding site of an antibody molecule from the same species, of the T-cell receptor gene, or another species. Gene pairs of the invention code, for example, for antibodies specific towards tumor-specific antigens, viral antigens, modified self antigens, bacterial or fungal antigens, autoimmune type disease antigens and the like. The invention further relates to expression vectors for the effective transfection of such cell types comprising such a recombinant gene pair, to methods for producing same and to pharmaceutical compositions comprising as active ingredient an effective quantity of lymphocytes transfected with such gene pairs.
    Type: Grant
    Filed: May 4, 1993
    Date of Patent: May 25, 1999
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Zelig Eshhar, Gideon Gross, Tova Waks
  • Patent number: 5766861
    Abstract: A method for screening or detection of a non-enzyme catalytic polypeptide or protein for the conversion of a substrate S to a product P is provided, in which a preparation containing the potential catalyst is contacted with the substrate S immobilized to a support and the immobilized product P obtained is detected, preferably by immunoassay. The method is preferably used for the screening of hybridoma supernatants for catalytic monoclonal antibodies that catalyze acyl transfer reactions, e.g., hydrolysis or aminolysis, condensation reactions and resolution of enantiomers.
    Type: Grant
    Filed: August 22, 1995
    Date of Patent: June 16, 1998
    Assignees: Yeda Research and Development Company Ltd., Yissum Research and Development Co. of the Hebrew University of Jerusalem
    Inventors: Zelig Eshhar, Bernard S. Green, Dan S. Tawfik